FDA As Drug Developer: Voucher For AstraZeneca, Orphan Indication For Wellstat
Executive Summary
Hoping to head off shortage of another product, FDA’s intervention gives both Wellstat and AstraZeneca quicker paths to market for their drugs in what could almost be a regulatory fairytale.
You may also be interested in...
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
US FDA’s New Drug Median Review Time Held Steady At Eight Months In 2021
The median review time for novel agents at CDER hasn’t changed in five years. Our infographic offers a look at the tortoises and hares (all of them winners because they got approved).
US Q4 Consumer Health Earnings Preview: Inflation Impact Follows Pandemic-Driven Disruption
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.